AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02854904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine intervention
Description: Immune effect of alpha-2 agonist to arthrodesis. Dexmedetomidine as a immune control anesthesic in patients undergoing to arthrodesis. Alpha-2 agonist to general anaesthesia.
Study NCT02854904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo controlled
Study NCT01819311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in anxiety and its disorders.
Study NCT01819311 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Attention Task
Description: At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe replaces the neutral stimulus and the threatening stimulus with equal probability.
Study NCT02343276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: Nitroglycerin (200 micrograms) + saline solution 10 ml in radial artery after sheath insertion
Study NCT02343276 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (saline solution 10 ml) in radial artery after sheath insertion
Study NCT04234776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: (0,75 mg/kg) saline solution (15 mg) Escitalopram (5 mg) Aripiprazole
Study NCT04234776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: (0,75 mg/kg) saline solution (15 mg) Escitalopram (5 mg) Aripiprazole
Study NCT04234776 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cognition
Description: Composite tools
Study NCT03142035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest 2 MG
Description: Dienogest is a fourth-generation progestin of 19-nortestosterone derivative, that has been shown to improve endometriosis associated pelvic pain. It is well tolerated with no androgenic, glucocorticoid or mineralocorticoid activity. Dienogest creates a hyperprogestogenic and hypoestrogenic environment that initially induces a secretory state and then a decidualization of the ectopic endometrium and finally its atrophy. It also inhibits aromatase and COX-2 expression as well as prostaglandin E2 production in endometriotic stromal cells. It also normalizes the activity of natural killer cells and decreases the release of interleukin-1b by macrophages. These anti-inflammatory properties further help in reducing the size of endometriotic lesions
Study NCT03142035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gonapeptyl
Description: gonadotropic releasing hormone agonist
Study NCT03142035 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: IVF/IVF+ART
Description: In-vitro fertilization +/- assisted reproductive technology
Study NCT03142035 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVF/IVF+ART
Description: In-vitro fertilization +/- assisted reproductive technology
Study NCT03142035 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF/IVF+ART
Description: In-vitro fertilization +/- assisted reproductive technology
Study NCT02668822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENG 125 μg + E2 300 μg vaginal ring (MK-8342B)
Description: Medicated vaginal ring
Study NCT02668822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal ring
Description: Placebo vaginal ring
Study NCT02668822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 400-mg tablets, to be taken orally, were provided to the participants for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may have taken 400 mg every 4 hours as needed for pelvic pain/cramping.
Study NCT02668822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 400-mg tablets, to be taken orally, were provided to the participants for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may have taken 400 mg every 4 hours as needed for pelvic pain/cramping.
Study NCT00594620 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flav-ein capsules
Description: Soy/isoflavone supplementation
Study NCT00594620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02418117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stereolitographic template
Description: Flapless (atraumatic) dental implants insertion with the aid of a stereolitographic template.
Study NCT06231459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab 140 mg was administered intramuscularly every two weeks at the discretion of their physiciansm according to LDLc response. Clinical-demographic and anthropometry data were collected during a direct interview. Blood sample was processed to obtain glycated hemoglobin complete blood count and serum lipids. Likewise, flow cytometry was used to characterize baseline circulating M1-, M2-macrophages and monocytes. Multiplexing of plasma samples was used to compare plasma fraktaline, IL-1, IL-4, IL-6, IL-8, IL-10, MCP-1 and TNF-alpha. Endpoints consisted of: 1) lower serum lipids; 2) modification of pro-inflammatory mediators (neutrophils, lymphocytes, NtLR, soluble pro-inflammatory cytokines).
Study NCT00903747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prucalopride
Description: 2-10 mg prucalopride
Study NCT00903747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: moxifloxacin
Description: 400 mg moxifloxacin (Group 2a)
Study NCT00903747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (Group 2b)
Study NCT02168894 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Group 1: Acupuncture sessions with electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, take a 2 week break. After that, participant randomly assigned to receive 12 sessions of acupuncture with electrical stimulation as before or not have anymore sessions in this study.~Group 2: Acupuncture sessions without electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, will take a 2 week break. After that, participant randomly assigned to receive 12 extra sessions of acupuncture without electrical stimulation or not have anymore sessions in this study.~Group 3: Acupuncture sessions 3 times per week over 4 weeks for a total of 12 sessions. Participant may or may not have electrical stimulation at these sessions. These sessions will begin 14 weeks after enrollment.
Study NCT02168894 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Group 1: Acupuncture sessions with electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, take a 2 week break. After that, participant randomly assigned to receive 12 sessions of acupuncture with electrical stimulation as before or not have anymore sessions in this study.~Group 2: Acupuncture sessions without electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, will take a 2 week break. After that, participant randomly assigned to receive 12 extra sessions of acupuncture without electrical stimulation or not have anymore sessions in this study.~Group 3: Acupuncture sessions 3 times per week over 4 weeks for a total of 12 sessions. Participant may or may not have electrical stimulation at these sessions. These sessions will begin 14 weeks after enrollment.
Study NCT02168894 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve Function Tests
Description: Nerve function tests consisting of hand tasks and balance evaluation performed at visit before acupuncture, and at end of study visit.
Study NCT02168894 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Function Tests
Description: Nerve function tests consisting of hand tasks and balance evaluation performed at visit before acupuncture, and at end of study visit.
Study NCT02168894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion at baseline, visit before acupuncture, after 6th and 12th acupuncture session, and at end of study visit.
Study NCT02168894 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Questionnaire completion at baseline, visit before acupuncture, after 6th and 12th acupuncture session, and at end of study visit.
Study NCT03252314 — intervention group
Intervention type: DEVICE
Intervention: Second-generation hydrogel coils
Description: Hydrogel coils 90% by length
Study NCT04195659 — intervention group
Intervention type: PROCEDURE
Intervention: Mastectomy and chest masculinization
Description: A surgical procedure in which the breasts are removed and the chest is given a masculine contour.
Study NCT03524105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program for Parents (Parenting Program)
Description: Program for Parents (Parenting Program) is implemented by a mental health professional and offered to groups of \~15 parents during the school day and during after school hours. The Program for Parents includes 2-hour sessions provided weekly over a 4-month period. The Program for Students (Friends School Social Emotional Learning Program) is implemented by classroom teachers in the classroom with 90 minute lessons and activities once a week for 14 weeks
Study NCT03524105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Thrive Professional Learning
Description: Professional Learning is delivered to teachers in groups of 20-40 4 times a year over a two-year period. Professional Learning is delivered to leaders in groups of 20 - 40 three times a year over the same two-year period.
Study NCT02311309 — intervention group
Intervention type: OTHER
Intervention: Control
Description: Control patients were defined as either transfusion using only pre ordered packed red blood cells or peroperative hemoglobin concentration >8 g/dL.
Study NCT02311309 — intervention group
Intervention type: OTHER
Intervention: Unanticipated bleeding
Description: Unanticipated bleeding was defined as either transfusion above the pre ordered packed red blood cells or peroperative hemoglobin concentration \< 8 g/dL.
Study NCT02357641 — intervention group
Intervention type: OTHER
Intervention: retrospective echographic myocardial strain analysis refering to acute coronary syndrome
Description: retrospective evaluation for cut off value of circumferential and radial echographic strain parameters corresponding to acute coronary disease
Study NCT02152592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCM/Oxy1
Description: Controlled Release oxycodone 10 mg orally twice a day for 24 hours
Study NCT02152592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCM/Oxy2
Description: CR oxycodone 10 mg orally twice a day for 48 hours
Study NCT01523314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone - Cyclodextrin eye drops
Description: The study eye will receive the dexamethasone NP eye drops 3 times a day for 3 months. The subject will be handed an eye drop bottle at each monthly visit for self administration of the eye drops. Each eye drop container is to be marked with a date when first opened and discarded after 1 week (unless it contains a preservative).
Study NCT01523314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal Avastin injection +/- macular laser
Description: The study eye will receive standard laser and intravitreal injections of Avastin for 3 months. Complete eye examination will be performed prior to drug administration.
Study NCT03145194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 2 x 90mg Ticagrelor tablets
Study NCT03145194 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x matching placebo tablets
Study NCT03263936 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Decitabine
Description: Dose Level #0: 5 mg/m2 Dose Level #1: 7.5 mg/m2 Dose Level #2: 10 mg/m2 Dose Level #3: 15 mg/m2 Dose Level #4: 20 mg/m2 given IV over __ hour on days 1 through 5
Study NCT03263936 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vorinostat
Description: Age \<18: 180 mg/m2/day once daily PO. Age≥18: 200 mg twice daily PO.
Study NCT03263936 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Filgrastim (G-CSF)
Description: Given on days 5 until evidence of ANC recovery (>500/µL)5µg/kg/dose IV or SQ (starting at hour 0)
Study NCT03263936 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: 30 mg/m2/day IV over 30 minutes (starting at Hour 0 - Immediately after G-CSF)
Study NCT03263936 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Description: 2000 mg/m2/day (Starting at Hour 0.5),IV over 3 hours, days 6-10
Study NCT05597059 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Learning Prediction
Description: Machine Learning Prediction
Study NCT01030458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine 5/10 mg per day plus valsartan 160 mg/day
Description: Amlodipine 5/10 mg/day plus valsartan 160 mg/day, once daily, in the morning
Study NCT01030458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day
Description: hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day, once daily, in the morning
Study NCT04234776 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cognition
Description: Composite tools
Study NCT05641038 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peloid treatment
Description: The patients in the first group; Peloid was applied to both feet at 42 °C for 2 weeks, 5 days a week, 10 sessions in total, 20 minutes each session. Peloid was applied in a layer of approximately 1.5-2 cm thick, then the foot was wrapped in a nylon bag and covered with a towel. After 20 minutes of application, the peloid layer was removed and disposed of in medical waste. The treatment area was cleaned with soft cloths moistened with hot water and the session was ended. In addition to peloid therapy, a home exercise program including joint range of motion, stretching and strengthening exercises for the 1st MTF with 3 sets of 10 repetitions was described for the patients to do simultaneously.
Study NCT05641038 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paraffin treatment
Description: The patients in the second group were given paraffin treatment on both feet by dipping method, for 2 weeks, 5 days a week, 10 sessions in total, 20 minutes each session. After the foot was dipped and removed 10 times, it was wrapped in a nylon bag and left for 20 minutes. Then the paraffin was peeled off the feet and disposed of in medical waste. Likewise, a home exercise program including joint range of motion, stretching and strengthening exercises for the 1st MTF with 3 sets of 10 repetitions was described for them to do simultaneously.
Study NCT03179280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin
Description: All participants used the rapid-acting insulin analogue aspart (NovoRapid®, Novonordisk A/S, Bagsvaerd, Denmark) and total insulin dose administered to each one for each test meal was known in advance, according to the insulin to carbohydrate ratio that had been calculated during the 2-week pre-study period.
Study NCT03248245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LOG-model
Description: Besides the LOG-manual, school owners and leaders receive economic compensation and the intervention team will supervise the implementation. School-owners, school leaders and teachers will participate in dialogue-seminars at the municipal level and the school level respectively. The aim is to discuss and agree on the goal and content of the work and discuss the experiences from the implementation. The main arena for discussing and practical implementation will be in local collaborating teams or resource teams in each school. The resource teams at schools will consist of various interprofessional competences in addition to the school leader. The main method in the LOG-model is the interchange and feedback process between the discussion of measures and the execution of these measures.
Study NCT03248245 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Ordinary practices related to interprofessional team collaboration
Study NCT04246580 — intervention group
Intervention type: PROCEDURE
Intervention: Indocyanine green-guided systematic pelvic lymphadenectomy
Description: Injection of Indocyanine green within the uterine cervix before to perform laparoscopic/robotic systematic pelvic lymphadenectomy
Study NCT02981277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transcricoid injection
Description: Lignocaine delivery using Transcricoid Injection
Study NCT02981277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spray as you go
Description: Lignocaine delivery using Spray as you go method
Study NCT01672606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Partial neuromuscular blockade with rocuronium with a TOF 0.70
Study NCT00623467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Description: Gadobutrol single injection 0.1 mmol/kg BW via IV bolus administration at 2mL/sec.
Study NCT04131517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Study Medication: Padsevonil Dosage formulation: Oral tablets; 400 mg BID (Part 1) and 200 mg BID (Part 2)
Study NCT04131517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon 30®
Description: Study Medication: Microgynon 30® Dosage formulation: Oral tablets Dose: Ethinyl estradiol 30 µg + levonorgestrel 150 µg
Study NCT00347763 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 10% permethrin in water applied as low volume spray
Study NCT03550131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Innovations in Dementia Empowerment and Action (IDEA)
Description: The IDEA intervention has the same exposure to treatment as the RDAD intervention. The behavioral component of the treatment manual is adapted to incorporate 3 risk factors that are empirically known to affect midlife and older LGBT populations.These include: 1) identity management; 2) stigma-related adverse/traumatic life events; and 3) lack of social support. All other aspects of the treatment are preserved.
Study NCT03550131 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reducing Disabilities in Alzheimer's Disease (RDAD)
Description: The RDAD intervention includes behavioral management training for caregiver and activities and exercise training for caregiver and care receiver.
Study NCT04395352 — intervention group
Intervention type: DEVICE
Intervention: Endocuff Vision (ECV)
Description: Detachable disposable (single-use) device that fits over the distal colonoscope end.
Study NCT03664284 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous disinfection
Description: The investigators will randomize 105 patient on two arms. The control group receiving no disinfection of the subcutaneous tissue (A) and intervention group, receiving disinfection of the subcutaneous tissue (B).
Study NCT00624728 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F Fluorothymidine PET CT
Description: 18 FLT will be provided by the Laboratoire des Radiopharmaceutiques- Université Bordeaux2, Hôpital Xavier Arnozan and prepared according to the method described by Grierson and Shields ( Grierson J, Shields A. Nucl Med Biol 27 :143-156 ; 2000).~Specific activity of 18FLT will be more than 37 GBq/µmol (>1Ci/µmol) corrected for decay at the end of bombardment of cyclotron target. Before tracer injection to patients, each dosis will be tested for pH and for radiochemical purity (> 95%) via HPLC technique and thin layer chromatography.~18FLT dosis will be injected intravenously to the patients (10 mL of salted isotonic solution with less than 10 % (v/v) of ethanol (USP). Administrated activity will be calculated estimating total body surface of patient (2,6 MBq/kg ou 0,07 mCi/kg) with maximal activity of 185 MBq.~PET acquisition will be realized as follows : Dynamic acquisition in 3D mode for 35 min, Iterative reconstruction (OSEM) with and without attenuation correction.
Study NCT01864798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Study NCT04966195 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: stereotactic body raiotherapy
Description: stereotactic body radiotherapy of hepatocellular carcinoma patients with portal vein tumor thrombosis
Study NCT03487640 — intervention group
Intervention type: PROCEDURE
Intervention: TARMR
Description: Transanal resection of rectal mucosa for at least 5cm in length.
Study NCT03487640 — intervention group
Intervention type: PROCEDURE
Intervention: LARSC
Description: We are going to suspend the rectum and to resect rigmarole hidgut Laparoscopically
Study NCT02104804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5mg
Description: Saxagliptin 5mg (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).